Carregant...
Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer
Combination treatment for non-small cell lung cancer (NSCLC) is becoming more popular due to the anticipation that it may be more effective than single drug treatment. In addition, there are efforts to genetically screen patients for specific mutations in light of attempting to administer specific a...
Guardat en:
| Publicat a: | Am J Cancer Res |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
e-Century Publishing Corporation
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4969399/ https://ncbi.nlm.nih.gov/pubmed/27508092 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|